title: Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial.
abstract: BACKGROUND
  The role of anticoagulants for the prevention of placental-mediated pregnancy complications is uncertain.
  
  
  OBJECTIVE
  Our aim was to investigate the effectiveness of dalteparin, a low-molecular-weight heparin, in preventing the recurrence of these complications in women without thrombophilia.
  
  
  METHODS
  Between August 1 2000 and June 20 2007, 116 pregnant women with: (i) <or= 16 weeks' gestation, (ii) no detectable thrombophilia, (iii) previous severe pre-eclampsia, newborn weight <or= 5th percentile, unexplained intrauterine death or abruptio placentae were randomized to either a prophylactic daily dose of dalteparin (n = 58) or no dalteparin (n = 58). The primary outcome was a composite of one or more of: severe pre-eclampsia, newborn weight <or= 5th percentile or major abruptio placentae. Secondary outcomes included non-severe pre-eclampsia, newborn weight at the 6-10th percentile and gestational age at delivery. Analyses were by intention to treat. P < 0.05 was considered to be significant. This study is registered as an International Standard Randomized Controlled Trial, number ISRCTN78732833.
  
  
  RESULTS
  Among the 110 women included in the final analysis, dalteparin was associated with a lower rate of the primary outcome [5.5% (n = 3/55) vs. 23.6% (n = 13/55), adjusted odds ratio (OR) 0.15, 95% confidence interval (CI) 0.03-0.70]. Secondary outcomes were not statistically different between the groups. Bleeding problems or thrombocytopenia did not occur.
  
  
  CONCLUSIONS
  In this pilot study, dalteparin is effective in decreasing the recurrence of placental-mediated complications in women without thrombophilia. Our results require confirmation in further randomized trials.
authors.affiliation: Division of Obstetrics Medicine, Department of Obstetrics and Gynaecology, CHU Sainte-Justine, Montreal, QC, Canada. evelyne_rey@ssss.gouv.qc.ca
authors.forename: E
authors.initials: E
authors.lastname: Rey
authors.forename: P
authors.initials: P
authors.lastname: Garneau
authors.forename: M
authors.initials: M
authors.lastname: David
authors.forename: R
authors.initials: R
authors.lastname: Gauthier
authors.forename: L
authors.initials: L
authors.lastname: Leduc
authors.forename: N
authors.initials: N
authors.lastname: Michon
authors.forename: F
authors.initials: F
authors.lastname: Morin
authors.forename: C
authors.initials: C
authors.lastname: Demers
authors.forename: S R
authors.initials: SR
authors.lastname: Kahn
authors.forename: L A
authors.initials: LA
authors.lastname: Magee
authors.forename: M
authors.initials: M
authors.lastname: Rodger
mesh_terms: D000328:Adult; D017985:Dalteparin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005313:Fetal Death; D006801:Humans; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D010865:Pilot Projects; D010920:Placenta / Q000503:physiopathology*; D011225:Pre-Eclampsia / Q000517:prevention & control; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy / Q000517:prevention & control*; D011256:Pregnancy Outcome; D055502:Secondary Prevention
chemical_list: D017985:Dalteparin